

INFORMAZIONI PERSONALI

Annamaria Catino



📍 Dipendente medico oncologo presso IRCCS Istituto Tumori "G. Paolo II" BARI
SSD Oncologi Medica Toracica

☎ +39-0805555357

✉ a.catino@oncologico.bari.it



CODICE FISCALE CTNNMR59D51A662W

| Data nascita 11/04/1959 | Bari, Italia

1985-1988

Laurea in Medicina e Chirurgia e Specializzazione in Oncologia
presso l'Università degli Studi di Bari

Esperienze lavorative

Dal 1995 , in qualità di medico oncologo presso l' Istituto Tumori "Giovanni Paolo II" di Bari , ha svolto attività clinica di ricerca e cura rivolte a pazienti affetti da patologia neoplastica.

Dal 2010 tale attività è principalmente rivolta in ambito di Oncologia Toracica , sia in forma di assistenza clinica che come ricercatore dedicato a Trials clinici e translazionali riguardanti le neoplasie pleuro-polmonari, comprendenti terapie target ed innovative quali l'immunoterapia .

L'attività professionale in ambito oncologico è anche rivolta allo studio ed alla prevenzione del tabagismo , comprese attività rivolte ai giovani in ambito scolastico e l' attivazione del Centro per la disassuefazione tabagica dell'Istituto Oncologico di Bari , censito dall'Istituto Superiore di Sanità.

A tali attività si sono aggiunti l'organizzazione di eventi dedicati alla informazione e sensibilizzazione riguardo ai rischi tabacco-correlati oltre alla pubblicazione di articoli scientifici sull'argomento su riviste ad elevato Impact Factor.

Attualmente è titolare di incarico di alta professionalità " Percorsi terapeutici innovativi nelle neoplasie della pleura e del polmone ed implementazione dell'arruolamento in trials clinici , studio della patologia polmonare in ottica di genere, studio del tabagismo nell'ambito della prevenzione e dell'approccio terapeutico globale in oncologia toracica".

Società Scientifiche

- Team Multidisciplinare "Neoplasie Pleuropolmonari " presso IRCCS-Istituto Tumori "G. Paolo II" di Bari (Vice Coordinatore)
- International Association for the Study of Lung Cancer (IASLC),
- Associazione Italiana di Oncologia Medica (AIOM),
- Women Against Lung Cancer in Europe (WALCE)
- Gruppo Italiano Salute e Genere (GiseG)
- Membro Topical Advisory Panel – Oncology della Rivista *Journal of Clinical Medicine* (IF 4.2)



•

Principali Pubblicazioni Scientifiche

1. Mastroianni CM, Jirillo E, De Simone C, Grassi PP, Maffione AB, **Catino AM**, Vullo V, Misefari A, Delia S. Humoral and cellular immune responses to Salmonella typhi in patients with typhoid fever. "J Clin Lab Anal. 1989;3(3):191
2. Gargano G, **Catino A**, Correale M, Abbate I, Pellecchia A. "The Krukenberg tumor. A case report". Clin Exp Obst Gyn 18(1):1-2,1991
3. Gargano G, **Catino A**, Correale M, Lorusso V et al. "Prognostic factors of epithelial ovarian cancer". Eur J Gynecol Oncol 13(suppl 1):45-55,1992
4. Correale M, Abbate I, **Catino A**, Tedone T et al. "Serum levels of TAG 72 and CA 15-3 in patients with gynaecological neoplasm". Eur J Gynaecol Oncol 13(suppl 1):82-84, 1992
5. **Catino A**, Lorusso V, Gargano G, Pellecchia A, Marzullo F, De Lena M. "Metastatic involvement of the stomach secondary to breast carcinoma: a case report". Eur J Gynaecol Oncol 13(suppl 1):85-88,1992
6. Abbate I, Correale M, Gargano G, Tedone T, Izzi G, **Catino A** et al. "Tumor Necrosis Factor and soluble Interleukin-2 receptor: two immunological biomarkers in female neoplasms". Eur J Gynaecol Oncol 13(suppl 1):92-96, 1992
7. Correale M, Abbate I, Gargano G, **Catino A**, Dragone D et al. "Analytical and clinical evaluation of a new tumor marker in breast cancer:CA 27.29". Int J Biol Markers 7(1):43-46,1992
8. Gargano G, **Catino A**, Correale M, Lorusso V et al. "Krukenberg Tumor: a report of six cases". Eur J Gynaecol Oncol 13(5):431-435,1992
9. Correale M, Abbate I, Dragone CD, Tedone T, Musci MD, Gargano G, **Catino AM**, Bafunno AM, Grossi B. "Behaviour of four serum tumor markers in pregnant women. Int J Biol Markers. 1993; 8(3):198-9".
10. Lorusso V, Berardi F, Brandi M, Mastria A, Paradiso A, **Catino AM**, Tatulli C, De Lena M. "M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial

carcinoma” Tumori. 1993;79(3):191-4.

11. Correale M, Abbate I, Paradiso A, Schittulli F, Dragone CD, Tedone T, Gargano G, **Catino AM**, Musci MD, De Lena M. “pS2--a new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer” Cell Biophys. 1993; 22(1-3):101-10.
12. Lorusso V, **Catino A**, Leone B et al. “Carboplatin plus Ifosfamide as salvage treatment of epithelial ovarian cancer. A pilot study”. J Clin Oncol 10:1952-56, 1993
13. Correale M, Abbate I, Dragone CD, Tedone T, Gargano G, **Catino A**, Paradiso A, Addabbo L, Musci MD, De Lena M. “Serum and cytosolic levels of CA549 in breast cancer patients” Clin Exp Obstet Gynecol. 1993;20(4):264-7.
14. Lorusso V, Berardi F, Brandi M, Mastria A, Paradiso A, **Catino AM**, Tatulli C and De Lena M. “M-VECA (Methotrexate, Vinblastine, Epidoxorubicin and Carboplatin) in the treatment of advanced urothelial carcinoma”. Tumori 79:191-194, 1993
15. Correale M, Abbate I, Paradiso A, Schittulli F, Dragone CD, Tedone T, Gargano G, **Catino AM**, Musci M and De Lena M. “pS2-A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer”. Cell Biophysics 22:101-110,1993
16. Paradiso A, Mangia A, Barletta A, **Catino AM**, Giannuzzi A, Schittulli F, Radogna N, Longo S, Palmieri D, Marzullo F, et al. “Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer” Drugs. 1993;45 Suppl 2:68-74
17. Brandi M, De Mitrio A, DiTonno P, **Catino A**, Lorusso V and De Lena M. Oral versus intravenous CMF in metastatic breast cancer: a randomized study. Int J Oncol 4:559-565,1994
18. Lorusso V, **Catino AM**, Brandi M et al. Cyclophosphamide, Mitoxantrone and fluorouracil versus cyclophosphamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. Int J Oncol 4:767772, 1994
19. De Lena M, De Mitrio A, **Catino A** et al. Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. Int J Oncol 4:779-782, 1994
20. Lorusso V, Pezzella G, **Catino A** et al. Results of a clinical multicentric randomized phase II study of non-small cell lung cancer treated with vinorelbine-cisplatin versus vinorelbine alone. Int J Oncol 6:65-68, 1995

21. Gargano G, Zito FA, **Catino A**, Correale M, Abbate I, Besozzi A, Marzullo A, Attolico M. Ovarian fibroma. A report of three cases. *Eur J Gynaecol Oncol*. 1995;16(6):509-15.
22. De Lena M, Lorusso V, Bottalico C, Brandi M, De Mitrio A, **Catino A**, et al. Revertant and potentiating activity of Lonidamine in patients with ovarian cancer previously treated with platinum. *J Clin Oncol* 15 (10):3208-3213, 1997
23. Lorusso V, Carpagnano F, Di Rienzo G, **Catino A**, Cisternino M L, Guida M, Brandi M, Latorre A, Parisi S, Ricco R and De Lena M. Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC). *Int J Oncol* 8 :675-680, 1996
24. Lorusso V, Leone B, Di Vagno G, Manzione L, Palmeri S, Vallejo C, Machiavelli M, Nacci G, Bilancia D, Leonardi V, **Catino A**, Gargano G, Loverro G, Selvaggi L and De Lena M for GOCS (Gynecological Oncology Cooperative Study). Combined Carboplatin plus Ifosfamide and Cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. *Gynecol Oncol* 68:172-177, 1998
25. Lorusso V, **Catino A**, Schittulli F, Longo S, Racanelli A, Timurian A, Marzullo F, Simone G, Brandi M and De Lena M. Neoadjuvant chemotherapy with accelerated CNF plus G-CSF in patients with breast cancer tumors larger than three centimeters: a pilot study. *Int J Oncol* 12:1177-1181,1998
26. De Lena M, Latorre A, Calabrese P, **Catino A**, et al. High efficacy of Paclitaxel and Doxorubicin as first-line therapy in advanced breast cancer: a phase I-II study. *J Chemoth* 12(4):367-373, 2000
27. De Lena M, Lorusso V, Latorre A, Fanizza G, Gargano G, Caporusso L, Guida M, **Catino A**, et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. *Eur J Cancer* 37:364-368, 2001
28. Latorre A, De Lena M, **Catino A**, Crucitta E, Sambiasi D, Guida M, Misino A, Lorusso V. Epithelial ovarian cancer: second and third line chemotherapy (Review). *Int J Oncol* 20:179-186, 2002
29. **Catino A**, Crucitta E, Latorre A et al. Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. *Oncol Rep* 10:163-167, 2002
30. Gadaleta C, **Catino**, Ranieri G, et al. Hypoxic stop-flow perfusion with Mitomycin in the treatment of multifocal liver metastases. Usefulness of a vascular arterial stent to prevent iatrogenic lesions of the hepatic arterial wall. *J Exp Clin Cancer Res* 22, 4 (suppl):203-206, 2003
31. Lorusso V, Crucitta E, Silvestris N, **Catino A** et al. Phase I-II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. *Br J Cancer* 88(4):491-5,2003
32. Gadaleta C, Mattioli V, Colucci G, Cramarossa A, Lorusso V, Canniello E, Timurian A, Ranieri G,

Fiorentini G, De Lena M, **Catino A**

33. Radiofrequency thermal ablation of 40 lung neoplasms: preliminary results. *Am J Roentgenol* 183:361-368, 2004
34. Gadaleta C, **Catino A**, Ranieri G et al. Radiofrequency thermal ablation of 69 lung neoplasms. *J Chemother* 16(5):86-89, 2004
35. Gadaleta C, Coviello M, **Catino A** et al. Serum vascular endothelial growth factor concentrations in hepatocellular cancer patients undergoing percutaneously radiofrequency thermal ablation. *J Chemother* 16(5):7-10, 2004
36. Gadaleta C, **Catino A**, Mattioli V. Radiofrequency Thermal Ablation in the treatment of lung malignancies. *In vivo* 20:765-768, 2006
37. Gadaleta C, **Catino A**, Mattioli V. Stop-flow perfusion with Mitomycin-C as locoregional approach in the treatment of large-unresectable liver metastases. *In vivo* 20:769-772, 2006
38. Gadaleta C, **Catino A**, Mattioli V. Radiofrequency thermal ablation in the treatment of primary and secondary lung malignancies.. In: "Regional Oncotherapies", Ed. Paschalidis Medical Publications: 99-124, 2007
39. Massidda B, Attori F, Scanu A, Contu A, Farris A, **Catino A**, Palmeri S, Minerba L, Ionta MT. Dose-dense primary chemotherapy, as part of multidisciplinary treatment, for inoperable stage III B breast cancer- Long-term results of a phase II trial. *Oncology* 72 (1-2):17-26,2007
40. **Catino A**, Mattioli V, Gadaleta-Caldarola G, Fazio V, Ranieri G, Gadaleta CD. Lung RFA: Long-term results in a single-center experience. *J Clin Oncol* 2008;26, 158 (part I):7528
41. Gadaleta C, **Catino A**, Ranieri G, Fazio V, Gadaleta-Caldarola G, Cramarossa A, Armenise F, Canniello E, Vinciarelli G, Laricchia G, Mattioli V. Single-step therapy- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. *In Vivo* 23 (5):813-20, 2009
42. Gadaleta C, **Catino A**, Rubini G, Ranieri G, Fazio V, Gadaleta-Caldarola G, Vinciarelli G, Armenise F, Gaudiano A, Mattioli V.
43. Precision pulmonary trans-arterial chemoembolization (PPTACE) plus percutaneous RFA for unresectable lung neoplasms: Initial experience in twelve cases. *Proc ASCO J Clin Oncol* 2009; 27,15S (part I):7593

44. Izzo F, **Catino AM**, Vogl TJ, Middleton M, Valle JV, Fiore F, Gadaleta CD, Pirotta RM, Martignoni M, Laffranchi B. Phase II trial of nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP) in patients with hepatocellular carcinoma (HCC): First step results. *J Clin Oncol* 2009; 27,15S (part I):4593
45. Galetta D, Silvestris N, **Catino A**, Colucci G. Peripheral Skin Edema as Unusual Toxicity in Three Patients with Advanced Non-small Cell Lung Cancer Treated with Pemetrexed Alone or in Combination with Cisplatin. *J Thorac Oncol.* 2011 ;6(11):1964
46. Landi L, **Tiseo M**, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, **Banna G**, **Catino A**, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. *Clin Lung Cancer* 2014
47. Galetta D, Cinieri S, **Pisconti S**, Gebbia V, Morabito A, Borsellino N, Maiello E, Febraro A, **Catino A**, Rizzo P, Montrone M, Misino A, Logroscino A, Rizzi D, Di Maio M, Colucci G. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. *Clin Lung Cancer* 2014
48. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. (**Catino** in LIFE study team collaborators). *J Cancer Res Clin Oncol* 2014, 140 (10):1783-93
49. Mangia A, Partipilo G, Schirosi L, Saponaro C, Galetta D, **Catino A**, Scattone A, Simone G. Fine Needle Aspiration Cytology: A Tool to Study NHERF1 Expression as a Potential Marker of Aggressiveness in Lung Cancer. *Mol Biotechnol* 2015
50. Galetta D, **Catino A**, Misino A, Logroscino A, Fico M. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease. *Tumori.* 2015 Jun 5;0(0):0. doi: 10.5301/tj.5000364.
51. Galetta D, **Catino A**, Misino A, De Ceglie A, Logroscino A, Simone G, Natalicchio MI. Bladder and gastric metastases from lung adenocarcinoma harboring codon 13 KRAS mutation: a case report with unusual clinical outcome. *Tumori.* 2015 Sep 9;101(5): e138-40. doi: 10.5301/tj.5000358.
52. Petriella D, De Summa S, Lacalamita R, Galetta D, **Catino A**, Logroscino AF, Palumbo O, Carella M, Zito FA, Simone G, Tommasi S. miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome. *Tumor Biol* 2015

53. **Catino A** et al. An interdisciplinary early simultaneous palliative approach in advanced lung cancer (a-LC): Preliminary data in outpatient setting experience. *J Clin Oncol* 33, 2015 (suppl 29S; abstr 138)
54. **Catino A**, Misino A, Scattone A, Caldarola L, Petroni S, Logroscino A, Montagna ES, Serio G, Simone G, Galetta D. Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma. *Transl Lung Cancer Res.* 2016;5(1):145-9.
55. Galetta D, **Catino A**, Misino A. Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target. *Transl Lung Cancer Res.* 2016 ;5(1):143-4
56. Barni S, Maiello E et al. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. *Lung Cancer* 2015; 90 (2):234-42
57. Galetta D, **Catino A**, De Palma ME, Acito A, Lacalamita R, Longo M, De Summa S, Di Lauro A, D'Ecclesiis F, Giotta F; "Smoke-free" Task Force, Oncology Institute "Giovanni Paolo II", Bari, Italy. 40P A survey on smoking and tobacco control perceptions from physicians and employees working in an Italian cancer center. *J Thorac Oncol.* 2016 Apr;11(4 Suppl): S72. doi: 10.1016/S1556-0864(16)30154-X
58. Daniele A, Abbate I, Oakley C, Casamassima P, Savino E, Casamassima A, Sciortino G, Fazio V, Galetta D, Caldarola G, **Catino A**, Giotta F, De Luca R, Divella R. Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review. *Int J Biochem Cell Biol.* 2016; 77:91-101. doi: 10.1016/j.biocel.2016.06.00
59. Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, **Catino A**, Maiello E, Arizio F, Novello S. Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. *Lung Cancer* 111 (2017) 30–37
60. Capelletto E, Rapetti SG, Demichelis S, Galetta D, **Catino A**, Ricci D, Moretti AM, Bria E, Pilotto S, Bruno A, Valmadre G, Bandelli GP, Trisolini R, Gianetta M, Pacchiana MV, Vallone S, Novello S. Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a

respiratory disease. Clin Respir J, 2017

61. **Catino A**, Misino A, Logroscino A, Montagna ES, Galetta D. Cancer, hearth diseases and common risk factors: smoke. Springer International 2017, C. Lestuzzi et al. (eds), Manual of Cardio-oncology, DOI 10.1007/978-3-319-40236-9_2
62. Garassino MC, Crinò L, **Catino A**, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: results from the Italian cohort of an expanded access program. Tumour Biol. 2018;40(11):1010428318815047. doi: 10.1177/1010428318815047
63. Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S, Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albin A, Harari S, Barbieri F, Capelletto E, **Catino AM**, Cavone D, De Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A, Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio G. Pathologic grading of malignant pleural mesothelioma: an evidence-based proposal. J Thorac Oncol. 2018 Nov;13(11):1750-1761. doi: 10.1016/j.jtho.2018.07.002
64. **Catino A**, La Forgia D, Scattone A, Dentamaro R, Lapadula V, Galetta D. Breast metastasis from malignant pleural mesothelioma: a rare challenging entity. J Thorac Oncol. 2018 Jul;13(7):e117-e118. doi: 10.1016/j.jtho.2018.02.028
65. Scattone A, **Catino A**, Schirosi L, Caldarola L, Tommasi S, Lacalamita R, Montagna ES, Galetta D, Serio G, Zito FA, Mangia A. Discordance between FISH,IHC, and NGS analysis of ALK Status in advanced non-small cell lung cancer (NSCLC): a brief report of 7 cases. Transl Oncol. 2019 Feb;12(2):389-395. doi: 10.1016/j.tranon.2018.11.006.
66. **Catino A**, De Gennaro G, Di Gilio A, Facchini A, Galetta D, Palmisani J, Porcelli F, Varesano N. Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma . Cancers **2019**, 11, 831; doi:10.3390/cancers11060831

67. Bafunno D, Catino A, Lamorgese V, Pizzutilo P, Di Lauro A, Petrillo P, Lapadula V, Mastrandrea A, Ricci D, Galetta D . Tobacco control in Europe: A review of campaign strategies for teenagers and adults. *Critical Reviews in Oncology / Hematology* 138 (2019) 139–147
68. Bafunno D, **Catino A**, Lamorgese V, Del Bene G, Longo V, Montrone M, Pesola P, Pizzutilo P, Cassiano S, Mastrandrea A, Ricci D, Petrillo P, Varesano N, Zacheo A, Galetta D. Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review. *J Thorac Dis* 2020 | <http://dx.doi.org/10.21037/jtd.2020.02.23>
69. Cortellini A, Friedlander A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerte J, Giusti R, Bria E, Cortinovis, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R (...). Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. *Clin Lung Cancer* 2020;S1525-7304(20)30204-7. doi: 10.1016/j.clc.2020.06.010.
70. Cortellini A, Tiseo M , Giusti R et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. *Cancer Immunol Immunother* 2020 doi: 10.1007/s00262-020-02613-9. Online ahead of print.
71. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M et al. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study . *European Journal of Cancer* 134 (2020) 19-28
72. Di Gilio A, **Catino A**, Lombardi A, Palmisani J, Facchini L, Mongelli T, Varesano N, Bellotti R, Galetta D, De Gennaro G, Tangaro S. Breath Analysis for Early Detection of Malignant Pleural Mesothelioma: Volatile Organic Compounds (VOCs) Determination and Possible Biochemical Pathways. *Cancers* **2020**, *12*, 1262; doi:10.3390/cancers12051262
73. Prelaj A, Lo Russo G, Proto L, Signorelli D, Ferrera R, Galli G ,.....**Catino A**. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced NoneSmall-Cell Lung Cancer: An External Validation. *Clin Lung Cancer*. 2020;S1525-7304(20)30005-X. doi:10.1016/j.clc.2020.01.005

74. Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, **Catino A**, Galetta D. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. *Clin Lung Cancer*. 2020;21(4):365-377.e5. doi:10.1016/j.clcc.2019.11.017
75. Grossi F, Genova C, Crinò L, et al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. *Eur J Cancer*. 2019;123:72-80. doi:10.1016/j.ejca.2019.09.011
76. Mariniello A, Ghisoni E, Righi L, **Catino A** et al. Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. *In Vivo*. 2019;33(6):2021-2026. doi:10.21873/invivo.11699
77. La Forgia D, **Catino A**, Dentamaro R, et al. Role of the contrast-enhanced spectral mammography for the diagnosis of breast metastases from extramammary neoplasms. *J BUON*. 2019;24(4):1360-1366.
78. Cortellini A, Leonetti A, **Catino A**, et al. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. *Clin Transl Oncol*. 2020;22(6):844-851. doi:10.1007/s12094-019-02193-w
79. Cortinovis D, Chiari R, **Catino A**, et al. Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases [published correction appears in *Anticancer Res*. 2020 Feb;40(2):1183]. *Anticancer Res*. 2019;39(8):4265-4271. doi:10.21873/anticancer.13590
80. Longo V, **Catino AM**, Montrone M, et al. Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?. *J Thorac Oncol*. 2019;14(8):e170-e172. doi:10.1016/j.jtho.2019.03.010

81. Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, **Catino A** et al. Maintenance with lanreotide in small-cell lung cancer expressing somatostatin receptors: A multicenter, randomized, phase 3 trial. *Lung Cancer*. 2019;134:121-126. doi:10.1016/j.lungcan.2019.06.011
82. Montrone M, Catino A, Palmieri A, Longo V, Galetta D. Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib. *Eur J Cancer* 2020; 138 (2020) 109e112
83. Bafunno D, Catino A, Lamorgese V, Longo V, Montrone M, Pesola F et al. Smoking Prevalence, Knowledge and Perceptions on Tobacco Control Among Healthcare Professionals: A Survey in an Italian Cancer Center. *J Commun Health* 2020. doi: 10.1007/s10900-020-00907-8
84. **Catino A**, Perrotti P, Cassiano S, Montrone M, Longo V, Galetta D. RET rearrangements in advanced lung cancer: a target to always look for. *Recenti Prog Med*. 2021 Feb;112(2):33e-36e. doi: 10.1701/3559.35382.
85. Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldessari C, Giusti R, D'Argento E, Grossi F, Santoni M, **Catino A**, et al. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study *Thorac Cancer*. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852.
86. Bafunno D, Romito F, Lagattolla F, Delvino VA, Minoia C, Loseto G, Dellino M, Guarini A, **Catino A**, et al. Psychological well-being in cancer outpatients during COVID-19 *J BUON*. 2021 May-Jun;26(3):1127-1134.
87. Bavaro DF, Pizzutilo P, **Catino A**, et al. Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study. *Open Forum Infect Dis*. 2021 Apr 13;8(6):ofab187. doi: 10.1093/ofid/ofab187. eCollection 2021 Jun.
88. Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Giusti R, Di Napoli M, Aprile G, Ermacora P, **Catino A**, et al. Influenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). *J Immunother Cancer*. 2021 May;9(5):e002619. doi: 10.1136/jitc-2021-002619.
89. Montrone M, Longo V, **Catino A**, Pizzutilo P, Galetta D. Efficacy of pralsetinib in a patient with advanced lung adenocarcinoma positive for RET rearrangement: the importance of Comprehensive Genomic Profiling. *Recenti Prog Med*. 2021 Jan;112(1):10e-13e. doi: 10.1701/3525.35132.

90. Longo V, **Catino A**, Montrone M, et al. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinibThorac Cancer. 2021 Jul;12(13):2031-2034. doi: 10.1111/1759-7714.13953.
91. Cortellini A, Friedlaender A, Banna GL,.... **Catino A**, et al. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression \geq 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.clcc.2020.06.010. Epub 2020 Jun 21.
92. Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, **Catino A** , et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \geq 50Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30.
93. Prelaj A, Rebutti SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, **Catino A**, Galetta D. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. Clin Lung Cancer. 2020 Jul;21(4):365-377.e5. doi: 10.1016/j.clcc.2019.11.017. Epub 2020 Mar 7.
94. Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, **Catino A**, et al. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyEur J Cancer. 2020 Jul;134:19-28. doi: 10.1016/j.ejca.2020.04.025. Epub 2020 May 23
95. Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, **Catino A**, et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \geq 50%: a multicenter study with external validationJ Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
96. Cortellini A, Leonetti A, **Catino A**, et al. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. Clin Transl Oncol. 2020 Jun;22(6):844-851. doi: 10.1007/s12094-019-02193-w. Epub 2019 Aug
97. La Forgia D, **Catino A**, Fausto A, et al. Diagnostic challenges and potential early indicators of breast periprosthetic anaplastic large cell lymphoma: A case report. Medicine (Baltimore). 2020 Jul 24;99(30):e21095. doi: 10.1097/MD.00000000000021095
98. Di Gilio A, Palmisani J, Ventrella G, Facchini L, **Catino A**, et al. Breath Analysis: Comparison among Methodological Approaches for Breath Sampling. Molecules. 2020 Dec 10;25(24):5823. doi: 10.3390/molecules25245823

99. Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, **Catino A**. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clin Lung Cancer*. 2020 Sep;21(5):e337-e348. doi: 10.1016/j.clcc.2020.01.005. Epub 2020 Mar 7.
100. Longo V, **Catino A**, Montrone M et al. Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement. *JTO Clin Res Rep*. 2020 Apr 18;1(2):100044. doi: 10.1016/j.jtocrr.2020.100044. eCollection 2020 Jun.
101. Banna GL, Tiseo M, Cortinovis DL, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, **Catino A**, et al. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. *Thorac Cancer*. 2022 Feb;13(3):483-488. doi: 10.1111/1759-7714.14256. Epub 2021 Dec 22. PMID: 34939342; PMCID: PMC8807213.
102. Nebhan CA, Cortellini A, Ma W, Ganta T,, **Catino A**, et al. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. *JAMA Oncol*. 2021 Dec 1;7(12):1856-1861. doi: 10.1001/jamaoncol.2021.4960. PMID: 34734989; PMCID: PMC8569601.
103. **Catino A**, Perrotti P, Cassiano S, Montrone M, Longo V, Galetta D. Riarrangiamenti di RET nelle neoplasie polmonari : quando è bene insistere nella ricerca di oncodriver [RET rearrangements in advanced lung cancer: a target to always look for.]. *Recenti Prog Med*. 2021 Feb;112(2):33e-36e. Italian. doi: 10.1701/3559.35382. PMID: 33624634.
104. Longo V, **Catino A**, Montrone M, Pizzutilo P, Annese T, Pesola F, Marech I, Cassiano S, Ribatti D, Galetta D. What Are the Biomarkers for Immunotherapy in SCLC? *Int J Mol Sci*. 2021 Oct 15;22(20):11123. doi: 10.3390/ijms222011123. PMID: 34681779; PMCID: PMC8538776.
105. Cortellini A, De Giglio A, Cannita K, Cortinovis DL, Cornelissen R, Baldessari C, Giusti R, D'Argento E, Grossi F, Santoni M, **Catino A**, et al. . Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. *Thorac Cancer*. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1. PMID: 33527756; PMCID: PMC7952794.

106. Vavalà T, **Catino A**, Pizzutilo P, Longo V, Galetta D. Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer. *Int J Mol Sci.* 2021 Nov 4;22(21):11942. doi: 10.3390/ijms222111942. PMID: 34769372; PMCID: PMC8584562.
107. Bafunno D, **Catino A**, Lamorgese V, Longo V, Montrone M, Pesola F, et al. Smoking Prevalence, Knowledge and Perceptions on Tobacco Control Among Healthcare Professionals: A Survey in an Italian Cancer Center. *J Community Health.* 2021 Jun;46(3):597-602. doi: 10.1007/s10900-020-00907-8. PMID: 32789714.
108. Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Giusti R, Di Napoli M, Aprile G, Ermacora P, **Catino A**, et al; FICOG group (Federation of Italian Cooperative Oncology Groups). INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). *J Immunother Cancer.* 2021 May;9(5):e002619. doi: 10.1136/jitc-2021-002619. PMID: 34016723; PMCID: PMC8141439.
109. Montrone M, Longo V, **Catino A**, Pizzutilo P, Galetta D. Efficacia di pralsetinib in un paziente con adenocarcinoma polmonare in stadio avanzato positivo per riarrangiamento di RET: l'importanza del Comprehensive Genomic Profiling [Efficacy of pralsetinib in a patient with advanced lung adenocarcinoma positive for RET rearrangement: the importance of Comprehensive Genomic Profiling.]. *Recenti Prog Med.* 2021 Jan;112(1):10e-13e. Italian. doi: 10.1701/3525.35132. PMID: 33512367.
110. Bafunno D, Romito F, Lagattolla F, Delvino VA, Minoia C, Loseto G, Dellino M, Guarini A, **Catino A**, et al. Psychological well-being in cancer outpatients during COVID-19. *J BUON.* 2021 May-Jun;26(3):1127-1134. PMID: 34268981.
111. Bavaro DF, Pizzutilo P, **Catino A**, Signorile F, Pesola F, Di Gennaro F, et al. Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study. *Open Forum Infect Dis.* 2021 Apr 13;8(6):ofab187. doi: 10.1093/ofid/ofab187. PMID: 34141817; PMCID: PMC8204890.
112. Longo V, **Catino A**, Montrone M, Pizzutilo P, Pesola F, Marech I, Capone I, Prelaj A, Galetta D. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib. *Thorac Cancer.* 2021 Jul;12(13):2031-2034. doi: 10.1111/1759-7714.13953. Epub 2021 May 19. PMID: 34008923; PMCID: PMC8258364.
113. **Catino A**, Lacalamita R, De Summa S, Pesola F, Tommasi S, Galetta D. Multiple Genetic Alterations as Resistance Mechanism during Second Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. *Diagnostics* 2022, Volume 12, Issue 3, 682

Principali Trials clinici condotti in qualità di Ricercatore Responsabile/Associato (2010-2021)

MARQUEE Study. A Phase 3, Randomized, Double-blinded, Placebo Controlled, Study of ARQ 197 plus Erlotinib vs Placebo plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous Non-Small Cell Lung Cancer (NSCLC)- Sub-Investigator

Trial A8081014 (PROFILE 1014) PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS- Sub-investigator

G 04-2011 Study(FONICAP) - TERAPIA DI MANTENIMENTO CON LANREOTIDE NEI PAZIENTI CON MICROCITOMA POLMONARE (LD/ED) ESPRIMENTI I RECETTORI SST IN RISPOSTA DOPO UNA 1^a LINEA DI TRATTAMENTO (CT/RT) STANDARD – Sub- investigator

Trial I4C-MC-JTBB A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First Line Treatment in Advanced or Metastatic NSCLC Patients with Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment with Erlotinib –Sub-investigator

The ASSESS Study: A diagnostic Study of European and Japanese advanced NSCLC patients to evaluate suitable sample types for EGFR testing – Sub-investigator

Trial SELECT-1 “Studio di fase III in doppio cieco, randomizzato, controllato verso placebo, per valutare l’efficacia e la sicurezza di **selumetinib** (AZD6244; ARRY-142886) in combinazione con docetaxel in pazienti che ricevono una seconda linea di trattamento per il polmone non a piccole cellule metastatico o localmente avanzato con mutazione KRAS positiva (Stadio IIIB-IV)” – Sub-investigator

GO28915 – OAK Trial:A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY. Sub-investigator

BR-31 Trial “STUDIO PROSPETTICO DI FASE III, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO, RANDOMIZZATO, DELL'ADIUVANTE MEDI4736 NEL TUMORE AL POLMONE NON A PICCOLE CELLULE COMPLETAMENTE ASPORTATO”.Principal Investigator

I3Y-MC-JPBX Trial: “Studio randomizzato di fase II di ABEMACICLIB (LY2835219) versus Docetaxel in pazienti con tumore al polmone non a piccole cellule di istotipo squamoso in stadio IV, precedentemente trattati con una chemioterapia a base di platino” – Principal Investigator

OSE Trial EudraCT 2015-003183-36: Sperimentazione con gruppo parallelo randomizzato di fase III trial di OSE 2101 come 2° linea dopo precedente insuccesso di chemioterapia a base di platino o come 3° linea dopo insuccesso di terapia a base di platino e insuccesso degli inibitori del checkpoint, a confronto con il

trattamento standard (docetaxel o pemetrexed) in pazienti positivi ad HLA-A2 con carcinoma polmonare non a piccole cellule (IIIB) non trattabile con radioterapia oppure metastatico" Sub-investigator

MORAB- NCT02357147 Trial. "A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma". Sub-investigator

Check-Mate Trial 209-743. Studio di fase III, randomizzato in aperto di Nivolumab in combinazione con Ipilimumab rispetto a Pemetrexed con cisplatino o carboplatino come terapia di prima linea nel mesotelioma pleurico non resecabile". Principal Investigator

"ETOP-BEAT MESO Trial" . A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma". Principal investigator

AUTORIZZAZIONE DATI PERSONALI

Dichiaro che le informazioni riportate nel presente Curriculum Vitae sono esatte e veritiere.

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali"

Bari , 24/10/2021

Firma

